INOVIO director exercises RSUs for 972 shares

INOVIO PHARMACEUTICALS director David B. Weiner acquired 972 shares of common stock through an RSU conversion.

Rhea-AI Filing Summary

INOVIO PHARMACEUTICALS director David B. Weiner acquired 972 shares of common stock through an RSU conversion. On February 26, 2026, 972 restricted stock units vested and were exercised at $0.00 per share, converting into 972 common shares.

These units were part of a 2,916‑unit grant made on February 27, 2023, vesting in three equal installments of 972 units on February 26 of 2024, 2025, and 2026. After this transaction, Weiner directly holds 87,592 shares of INOVIO common stock, and no restricted stock units from this grant remain outstanding.

Insider Trade Summary

972 shares exercised/converted

Exercise 2 txns

Insider Weiner David B.

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit	972	$0.00	$0.00
Exercise	Common Stock	972	$0.00	$0.00

Holdings After Transaction: Restricted Stock Unit — 0 contracts (Direct); Common Stock — 87,592 shares (Direct)

Footnotes (1)

1. F1. Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units granted on February 27, 2023 was as follows: 972 shares vested on February 26, 2024; 972 shares vested on February 26, 2025; and 972 shares vested on February 26, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

FAQ

What insider transaction did INOVIO (INO) director David B. Weiner report?

David B. Weiner reported acquiring 972 INOVIO common shares through conversion of restricted stock units. The RSUs vested on February 26, 2026 and were exercised at zero cost, increasing his directly held common stock position to 87,592 shares after the transaction.

How many INOVIO (INO) shares did the RSU conversion generate?

The RSU conversion generated 972 shares of INOVIO common stock. These shares came from a restricted stock unit award granted in February 2023, which vested in three equal installments. The February 26, 2026 vesting tranche was fully settled into common shares in this transaction.

What was the vesting schedule for David Weiner’s INOVIO (INO) RSU grant?

The 2,916 restricted stock units granted on February 27, 2023 vested in three installments. 972 units vested on February 26, 2024; another 972 on February 26, 2025; and the final 972 on February 26, 2026, which were converted into common stock in this filing.

Did David Weiner pay cash for the INOVIO (INO) shares acquired?

No cash was paid for the shares acquired in this transaction. The 972 INOVIO common shares were received upon exercise and settlement of vested restricted stock units at a stated price of $0.00 per share, as part of his equity compensation award.

How many INOVIO (INO) shares does David Weiner own after this Form 4?

After this Form 4 transaction, David Weiner directly owns 87,592 shares of INOVIO common stock. This reflects the addition of 972 shares from the vested restricted stock units converted on February 26, 2026, as disclosed in the ownership totals following the transaction.

Can INOVIO (INO) restricted stock units be settled in ways other than shares?

Yes, the restricted stock units can be settled in shares of common stock, cash, or a combination. In this case, the vested 972 units were settled in INOVIO common shares, but the award terms also allow for cash or mixed settlement at the company’s discretion.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/27/2026 - 04:44 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Weiner David B.

(Last) (First) (Middle)

660 W. GERMANTOWN PIKE

SUITE 110

(Street)

PLYMOUTH MEETING PA 19462

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
INOVIO PHARMACEUTICALS, INC. [ INO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/26/2026		M		972	A	(1)	87,592	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	02/26/2026		M			972	(1)	(1)	Common Stock	972	$0	0	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 2,916 restricted stock units granted on February 27, 2023 was as follows: 972 shares vested on February 26, 2024; 972 shares vested on February 26, 2025; and 972 shares vested on February 26, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

Remarks:

	/s/ David B. Weiner	02/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.